UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/594,418	12/28/2006	Simon Poon	123-03	8065
23713 7590 08/01/2008 GREENLEE WINNER AND SULLIVAN P C 4875 PEARL EAST CIRCLE SUITE 200 BOULDER, CO 80301			EXAMINER	
			FRONDA, CHRISTIAN L	
			ART UNIT	PAPER NUMBER
			1652	
			MAIL DATE	DELIVERY MODE
			08/01/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)			
	10/594,418	POON ET AL.			
Office Action Summary	Examiner	Art Unit			
	CHRISTIAN L. FRONDA	1652			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>13 Jules</u> This action is FINAL . 2b)⊠ This Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ☐ Claim(s) 1-7,9,11-17,19,21-25,29 and 32 is/are 4a) Of the above claim(s) 1-7,9,11-17,19,29 and 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 21-25 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or Application Papers 9) ☐ The specification is objected to by the Examine	d 32 is/are withdrawn from consider the design of the desi				
10)☑ The drawing(s) filed on 26 September 2006 is/a Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correction 11)☐ The oath or declaration is objected to by the Ex-	drawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 1/08.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate			

Art Unit: 1652

DETAILED ACTION

1. Claims 1-7, 9, 11-17, 19, 21-25, 29, and 32 as listed in the claim set filed 06/13/2008 are pending in the instant Office Action.

2. Applicant's election with traverse of Group V (claims 21-25) in the reply filed on 06/13/2008 is acknowledged. The traversal is on the ground(s) that the claims as amended have a special technical feature in common which is a protein having the amino acid sequence of SEQ ID NO: 25. This is not found persuasive for the following reasons stated below.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features.

A same or corresponding technical feature shared between Groups I-VIII is an arabinogalactan protein (AGP) having the amino acid sequence of SEQ ID NO: 25. However, this same or corresponding technical feature has already been taught by Poon et al. ("Somatic Embryogenesis-Specific Arabinogalactan-Proteins in Cotton Cell Cultures," *In Vitro Cell. Dev. Biol. Animal* 38:134A Abstract no. p-1450, 2002 (Abstract Only); PTO form 1449 of IDS filed 01/03/2008).

Poon et al. teach isolated AGP from embryogenic cotton cell culture and suggests their use in to promote somatic embryogenesis in elite cotton cultivars (see Abstract). Because the AGP of Poon et al. and the recited AGP of the instant application are both from same biological source which is cotton (*Gossypium hirsutum*), then the AGP of Poon et al. would inherently posses the properties of the claimed AGP including having the amino acid sequence of SEQ ID NO: 25.

Thus, the technical feature is not special since it was known in the prior art and therefore cannot make a contribution over the prior art. Since the inventions lack the same or corresponding special technical feature, then the inventions listed as Groups I -VIII are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The requirement is still deemed proper and is therefore made FINAL.

Art Unit: 1652

3. Claims 21-25 are under consideration in this Office Action.

4. Claim 25 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. The claim as written expands the scope of claim 21 to include any protein of any amino acid sequence and structure comprising a phytocyanin-like domain of an embryogenic AGP.

Claim Rejections - 35 U.S.C. § 101

5. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

6. Claims 21-25 are rejected under 35 USC 101 because the claimed invention is directed to non-statutory subject matter.

The claims, as written, do not sufficiently distinguish over pro-embryogenic arabinogalactan protein (AGP) as they exist naturally because the claims do not particularly point out any non-naturally occurring differences between the claimed products and the naturally occurring products. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. *See Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claims should be amended to indicate the hand of the inventor, e.g., by insertion of "Isolated pro-embryogenic arabinogalactan protein". See MPEP 2105.

Art Unit: 1652

Claim Rejections - 35 U.S.C. § 112, 2nd Paragraph

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claim 25 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 25 recites the phrase "phytocyanin-like domain" which renders the claim vague and indefinite. The meaning of the phrase is not known and defined by the specification. The metes and bounds of the claim are uncertain since the specific amino acid sequence and structure of the "phytocyanin-like domain" are unclear. Appropriate correction is requested.

Claim Rejections - 35 USC § 102

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 10. Claims 21-25 are rejected under 35 U.S.C. 102(b) as being anticipated by Poon et al. ("Somatic Embryogenesis-Specific Arabinogalactan-Proteins in Cotton Cell Cultures," *In Vitro Cell. Dev. Biol. Animal* 38:134A Abstract no. p-1450, 2002 (Abstract Only); PTO form 1449 of IDS filed 01/03/2008).

Poon et al. teach isolated AGP from embryogenic cotton cell culture and suggests its use to promote somatic embryogenesis in elite cotton cultivars (see Abstract). Because the AGP of Poon et al. and the recited AGP of the instant application are both from same biological source which is cotton (*Gossypium hirsutum*), then the AGP of Poon et al. would inherently posses the properties of the claimed AGP including having the amino acid sequence of SEQ ID NO: 25. According to MPEP 2112.01 Composition, Product, and Apparatus Claims:

Application/Control Number: 10/594,418

Art Unit: 1652

"Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a *prima facie* case of either anticipation or obviousness has been established. *In re Best,* 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." *In re Spada,* 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the *prima facie* case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. *In re Best,* 562 F.2d at 1255, 195 USPQ at 433. See also *Titanium Metals Corp. v. Banner,* 778 F.2d 775, 227 USPQ 773 (Fed. Cir. 1985)".

Page 5

Therefore, the teachings of Poon et al. anticipate the claims.

Conclusion

- 11. No claim is allowed.
- 12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Thursday and alternate Fridays between 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nashaat Nashed can be reached on (571)272-0934. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300.
- 13. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

Art Unit: 1652

like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Christian L. Fronda/
Patent Examiner
Art Unit 1652